Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
TGTX similar filings
- 21 Jun 21 Amendments to Articles of Incorporation or Bylaws
- 10 May 21 TG Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results
- 16 Apr 21 Other Events
- 13 Apr 21 Changes in Registrant's Certifying Accountant
- 2 Mar 21 TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2020 Financial Results
- 8 Feb 21 UKONIQ is approved for adult patients with relapsed or refractory marginal zone lymphoma after at least one prior anti-CD20 based regimen
- 16 Dec 20 Entry into a Material Definitive Agreement
Filing view
External links
Exhibit 16.1
April 12, 2021
Securities and Exchange Commission
100 F Street N.E.
Washington, D.C. 20549
We have been furnished with a copy of the response to Item 4.01 of Form 8-K for the event that occurred April 12, 2021, to be filed by our former client, TG Therapeutics, Inc. We agree with the statements made in response to that Item insofar as they relate to our Firm.
Very truly yours,
/s/ CohnReznick LLP